DVD和VAD方案治疗初治多发性骨髓瘤的疗效和安全性分析
Open Access
- 14 June 2017
- journal article
- Vol. 38 (6), 542-544
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Novel Drug Combinations for the Management of Relapsed/Refractory Multiple MyelomaClinical Lymphoma Myeloma and Leukemia, 2014
- Efficacy and Safety of Pegylated Liposomal Doxorubicin in Combination With Bortezomib for Multiple Myeloma: Effects of Adverse Prognostic Factors on OutcomeClinical Lymphoma Myeloma and Leukemia, 2011
- Weekly Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone Is a Safe and Effective Therapy for Elderly Patients With Relapsed/Refractory Multiple MyelomaClinical Lymphoma Myeloma and Leukemia, 2010
- The importance of bone marrow examination in determining complete response to therapy in patients with multiple myelomaBlood, 2009
- Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myelomaCancer, 2006
- Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myelomaAnnals of Oncology, 2003
- A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced‐dose dexamethasone combination therapy in newly diagnosed multiple myeloma patientsCancer, 2002
- Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.1997
- Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimensJAMA, 1969